Related Experiment Video

Updated: Jun 11, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Rapamycin inhibits activator protein-1 but not nuclear factor-kappaB activity of mature bone marrow-derived dendritic

G-Y Wang1, G-H Chen, H Li

  • 1Liver Transplantation Institution, the Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.

Transplantation Proceedings
|July 13, 2010
PubMed

Insights

Rapamycin (Rapa) prevents organ transplant rejection by specifically inhibiting activator protein-1 in mature dendritic cells (DCs). This targeted action may enhance immune tolerance, offering a novel therapeutic approach.

Area of Science:

  • Immunology
  • Pharmacology
  • Cellular Biology

Background:

  • Rapamycin (Rapa) is an emerging immunosuppressive drug used to prevent allograft rejection.
  • Dendritic cells (DCs) play a crucial role in immune responses and transplant outcomes.
  • Understanding Rapa's impact on DC signaling is vital for optimizing its therapeutic use.

Purpose of the Study:

  • To investigate the effects of Rapamycin on intracellular signal transduction pathways in mature dendritic cells (DCs).
  • To elucidate the specific molecular targets of Rapa within DCs relevant to immunosuppression.

Main Methods:

  • Analysis of intracellular signaling pathways in mature DCs treated with Rapamycin.
  • Assessment of protein expression levels (p65, p50, IkappaBalpha) and transcription factor activation (AP-1).

Main Results:

  • Rapamycin did not significantly alter the expression of p65, p50, or IkappaBalpha in mature DCs.
  • Rapamycin markedly inhibited the activation of activator protein-1 (AP-1) in mature DCs.

Conclusions:

  • Rapamycin selectively modulates AP-1 activity in mature DCs, distinct from its effects on other NF-kappaB pathway components.
  • This specific inhibition of AP-1 by Rapa in DCs may underlie its efficacy in preventing allograft rejection and promoting immune tolerance.

More Related Videos

Development and Application of Rapamycin-regulated Tyrosine Phosphatases06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs08:13

Rapid Quantification of Mitogen-induced Blastogenesis in T Lymphocytes for Identifying Immunomodulatory Drugs

Published on: December 27, 2016

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for injury repair.